Clinical Summary: 

• Design/Population: Single-arm study evaluating the addition of inotuzumab ozogamicin to a modified hyper-CVAD plus blinatumomab regimen in patients with B-cell acute lymphoblastic leukemia.
• Key Outcomes: The regimen achieved high remission and MRD-negative response rates with a low relapse rate, without an apparent increase in toxicity.
• Clinical Relevance: These findings suggest that incorporating additional immunotherapy into frontline treatment may further improve depth and durability of response in B-cell ALL.

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses data presented at the 2026 ASCO Annual Meeting evaluating the addition of inotuzumab ozogamicin to a modified hyper-CVAD plus blinatumomab regimen in B-cell acute lymphoblastic leukemia.

The study demonstrated high remission rates, deep MRD-negative responses, and low relapse rates with a shortened chemotherapy backbone and reduced-dose inotuzumab, while maintaining a favorable safety profile.

These findings suggest that further incorporation of immunotherapy into frontline treatment strategies may continue to improve outcomes for patients with B-cell ALL and warrant additional investigation.

Transcript: 

Hi, my name is Dan DeAngelo, I'm chief of the division of leukemia at the Dana-Farber Cancer Institute in Boston, Massachusetts.

At this year's ASCO Annual Meeting in Chicago, Nicholas Short from MD Anderson presented provocative data evaluating the addition of inotuzumab ozogamicin to a modified hyper-CVAD plus blinatumomab regimen in patients with B-cell acute lymphoblastic leukemia (ALL). 

In this approach, patients received a shortened chemotherapy backbone consisting of 4 cycles of modified hyper-CVAD, along with reduced-dose inotuzumab ozogamicin and blinatumomab. What Dr Short was able to demonstrate was a very high remission rate, a high rate of MRD-negative responses, and a very low relapse rate.

Importantly, these outcomes were achieved without an apparent increase in toxicity. While the study requires further investigation, the findings suggest that adding additional immunotherapy to the current treatment approach may further improve outcomes for patients with B-cell ALL.

Overall, these results represent a promising step forward and support continued exploration of immunotherapy-based frontline treatment strategies in B-cell acute lymphoblastic leukemia.

Source: 

Nasr LF, Goulart H, Short NJ, et al. Long-term outcomes with addition of inotuzumab ozogamicin to HCVAD and sequential blinatumomab in adults with newly diagnosed B-ALL.Presented at the ASCO Annual Meeting. May 29 - June 2, 2026. Chicago, Illinois. Abstract 6515.